SRCIN1 and neoplasm: In conclusion, our studies pave the way for the development of therapeutic intervention to target the epistatic β-Catenin/TIC/G-CSF/PMN-MDSCs axis to restore an efficient anti-tumor immune response, and point to the clinical validity of p140Cap as a biomarker for prognostic patient stratification and for anti-Wnt/β-Catenin targeted therapy response prediction.